v3.26.3
License, Acquisition, Research and Collaboration and Sponsored Research Agreements - Additional Information (Details)
1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 74 Months Ended 77 Months Ended
Sep. 30, 2026
USD ($)
Sep. 29, 2026
USD ($)
Apr. 21, 2024
USD ($)
Apr. 19, 2024
USD ($)
Apr. 13, 2024
Dec. 03, 2021
USD ($)
IntegerItem
Oct. 04, 2021
USD ($)
Jul. 16, 2021
Jan. 25, 2021
USD ($)
Aug. 06, 2020
USD ($)
May 28, 2020
USD ($)
IntegerItem
Apr. 23, 2020
USD ($)
Nov. 30, 2020
USD ($)
shares
Sep. 30, 2026
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Mar. 31, 2023
USD ($)
Jun. 30, 2022
USD ($)
Dec. 31, 2024
USD ($)
Sep. 30, 2026
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2026
USD ($)
Sep. 30, 2026
USD ($)
Dec. 17, 2025
USD ($)
Nov. 07, 2023
shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                  
Research and development expenses                           $ 34,496,000 $ 15,695,000         $ 69,226,000 $ 47,587,000        
Mantle Therapeutics Inc.                                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                  
Asset acquisition percentage of outstanding stock acquisition   100.00%                                              
Payment to selling shareholders   $ 2,165,000                                              
Stelios Therapeutics Inc                                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                  
Development milestone paid                                     $ 6,000,000            
Asset acquisition date of acquisition               Jul. 16, 2021                                  
Asset acquisition percentage of outstanding stock acquisition               100.00%                                  
Payment to selling shareholders                                     6,000,000            
Milestone received                                     $ 1,300,000            
Maximum | Stelios Therapeutics Inc                                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                  
Payment to selling shareholders $ 12,500,000                                                
Adverum License Agreement | Adverum Biotechnologies Inc                                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                  
One-time up-front non-refundable fee paid                 $ 7,500,000               $ 7,500,000                
Development milestone paid                           3,500,000     $ 3,500,000                
Royalty payments description                                       The Company is obligated to pay Adverum tiered royalties ranging from high single-digits to sub teens based on annual aggregate worldwide net sales of Products (as defined in the Adverum Agreement).          
Research and development expenses                                       $ 0          
License agreement termination notice period                 120 days                                
Adverum License Agreement | Adverum Biotechnologies Inc | Maximum                                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                  
Development and regulatory milestones due                 $ 17,500,000                                
Commercialization milestones due                 $ 49,000,000                                
Cornell License Agreements | Cornell University                                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                  
License agreement termination notice period                     90 days                            
Number of license agreements | IntegerItem                     2                            
Upfront payment in cash                     $ 300,000                            
Notes issued                     1,300,000                            
Notes with outstanding principal exchanged                         $ 1,300,000                        
Cornell License Agreements | Cornell University | Common Stock [Member]                                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                  
Converted shares into common stock | shares                                                 126,258
Cornell License Agreements | Cornell University | Series A Convertible Preferred Stock                                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                  
Shares issued on debt exchanged | shares                         1,337,610                        
First Cornell License Agreements | Cornell University | Maximum                                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                  
Specific clinical and regulatory milestones due                     8,400,000                            
Second Cornell License Agreements | Cornell University                                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                  
Clinical and regulatory milestone paid                                   $ 100,000              
Second Cornell License Agreements | Cornell University | Maximum | Two Portfolios                                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                  
Specific clinical and regulatory milestones due                     4,300,000                            
Second Cornell License Agreements | Cornell University | Maximum | Third Portfolio                                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                  
Specific clinical and regulatory milestones due                     $ 600,000                            
Third Cornell License Agreements | Cornell University                                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                  
License agreement termination notice period     90 days                                            
License fee and initial data transfer fee     $ 600,000                                            
Annual data transfer fee     50,000                                            
Third Cornell License Agreements | Cornell University | Minimum                                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                  
Annual license maintenance fees     2,500                                            
Third Cornell License Agreements | Cornell University | Maximum                                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                  
Commercialization milestones due     100,000,000                                            
Annual license maintenance fees     25,000                                            
Regulatory milestone to be paid     $ 2,100,000                                            
Second Amendment To The Third Cornell License Agreement                                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                  
Research and development expenses                           0 0         400,000 100,000        
Payment to additional data transfer process                                               $ 100,000  
First UCSD License Agreement | Stelios Therapeutics Inc                                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                  
One-time up-front non-refundable fee paid                       $ 20,000                          
First UCSD License Agreement | Maximum | Stelios Therapeutics Inc                                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                  
Development and commercialization milestones due $ 4,800,000                         4,800,000           4,800,000   $ 4,800,000 $ 4,800,000    
Second UCSD License Agreement | Stelios Therapeutics Inc                                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                  
One-time up-front non-refundable fee paid                   $ 20,000                              
License agreement termination notice period 60 days                 60 days                              
Second UCSD License Agreement | Stelios Therapeutics Inc | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense                                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                  
One-time up-front non-refundable fees                                           20,000 20,000    
Second UCSD License Agreement | Maximum | Stelios Therapeutics Inc                                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                  
Development and commercialization milestones due $ 2,400,000                         2,400,000           $ 2,400,000   $ 2,400,000 $ 2,400,000    
Third UCSD License Agreement                                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                  
Research agreements term         2 years                                        
Third UCSD License Agreement | Stelios Therapeutics Inc                                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                  
One-time up-front non-refundable fee paid             $ 20,000                                    
License agreement termination notice period             60 days                                    
Development and commercialization milestones description                                       the Company to pay aggregate development and commercialization milestones of up to $4.0 million, and low- to mid-single digit royalties based on aggregate net sales          
Third UCSD License Agreement | Stelios Therapeutics Inc | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense                                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                  
Development milestone paid                               $ 100,000                  
One-time up-front non-refundable fees             $ 20,000                                    
Third UCSD License Agreement | Maximum | Stelios Therapeutics Inc                                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                  
Development and commercialization milestones due             $ 4,000,000                                    
Amended First UCSD Agreement                                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                  
Costs incurred for research       $ 700,000                                          
UCSD Sponsored Research Agreements | Stelios Therapeutics Inc                                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                  
Research and development expenses                           0           $ 0 $ 100,000        
Number of research agreements | IntegerItem           2                                      
Research agreements term           2 years                                      
Research agreement termination notice period           30 days                                      
Costs incurred for research           $ 5,600,000                                      
Payment to research and development                           $ 0 $ 0         500,000          
Amended UCSD Sponsored Research Agreement [Member]                                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                                  
Research and development expenses                                       5,700,000          
Payment to research and development                                       $ 5,700,000